Page 24 - GM_2018_6

businessnews

www .g lassonline.com

GERRESHEIMER

INCREASES IN REVENUES; SUCCESSFULLY

INTEGRATION OF SENSILE MEDICAL

Gerresheimer AG 3.9%. The third quarter now be brought to market 31.3m in the prior-year
significantly increased brought revenue growth by the pharma company quarter. The adjusted
revenues at constant in plastic pharmaceutical concerned. earnings per share after
exchange rates in the third packaging in Europe Adjusted EBITDA at non-controlling interests
quarter of the financial and notably also in India constant exchange rates came to EUR 1.02 in the
year 2018 (1 June to 31 and South America. decreased from EUR third quarter, compared
August 2018). Organic Demand for plastic vials 78.2m in the prior-year with EUR 1.00 a year
growth was likewise for prescription drugs in quarter to EUR 76.1m. earlier.
substantial, as was growth the USA was stable. In Two negative effects have Net financial debt
in the first three quarters. the prefillable syringes to be taken into account increased by EUR
“Our business is pulling business, demand here: An expense of EUR 193.1m to EUR 905.8m
ahead as expected – the generally remains very 1.4m was recognized in as of August 31, 2018,
third quarter went well. good despite a slight drop the third quarter due to primarily due to payment
We are consequently in customer call-off orders the European Commission of the first instalment
confirming our revenue during the third quarter. decision on the exemption of the purchase price
guidance for this year. Medical plastic systems from network charges for Sensile Medical.
The integration of Sensile continue to be a revenue granted to large Calculated as the ratio
Medical, the technology growth driver, especially electricity-consuming of net financial debt to
group acquired in July, due to the inhaler project enterprises in 2012 and adjusted EBITDA over
is also proceeding fully in the USA. However, 2013. Furthermore, the last twelve months,
to plan. Its first product there was a decrease in adjusted EBITDA at adjusted EBITDA leverage
has gained European demand from a number constant exchange stood at 3.2x.
certification and is now of pharma customers rates for the Advanced Capital expenditure
being brought to market for whom Gerresheimer Technologies Division is totalled EUR 19.5m in
by the pharma company is the sole supplier. The a negative EUR 2.0m. the third quarter of 2018
concerned,” said Rainer moulded glass business Without these two effects, and EUR 45.1m in the
Beaujean, Speaker of the showed strong positive adjusted EBITDA at first three quarters of
Management Board and growth rates, most notably constant exchange rates the year. This included
CFO. in sales of cosmetic would have totaled EUR the expansion of inhaler
The Gerresheimer Group glass. With products 79.5m, EUR 1.3m higher production in the USA,
increased revenues such as injection vials, than in the prior-year additions to the product
at constant exchange ampoules and cartridges, quarter. The adjusted portfolio and enlargement
rates by 8.8% in the the recovery in the US EBITDA margin in the of production capacity. In
third quarter of 2018, business continued and third quarter of 2018 was the glass business, further
from EUR 335.0m in there was also growth 20.9%. Excluding the capital expenditure related
the prior-year quarter in Europe. Revenues at expense relating to the to the scheduled furnace
to EUR 364.4m. This constant exchange rates exemption for electricity overhaul in the USA as
includes EUR 3.5m in the new Advanced network charges and well as to modernization
from Sensile Medical, Technologies Division, excluding the new measures, tooling and
which was acquired which covers Sensile Advanced Technologies moulds.
in July 2018. On an Medical, came to Division, the adjusted Gerresheimer’s
organic basis – meaning EUR 3.5m in the third EBITDA margin came expectations for the
adjusted for exchange quarter. In September, to 22.0%, which, as financial year 2018,
rate effects and Sensile a wearable micro pump expected, is below the in each case assuming
Medical – revenues went from Sensile Medical 23.4% prior-year figure. constant exchange rates
up by 7.8% relative to the received CE certification Adjusted net income after and excluding acquisitions
prior-year quarter. In the for the European market. non-controlling interests and divestments,
first nine months of 2018, Custom-designed for the came to EUR 32.0m remain as set out in the
revenues at constant treatment of Parkinson’s in the third quarter, following. Exchange rates
exchange rates rose by disease, the pump can compared with EUR are calculated on the 2

glass machinery plants & accessories 6/2018
22